+++
title = "About"
slug = "about"
bgImage = "/img/aboutBg.jpg"
+++


Founded in 2018, Antios Therapeutics is a biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. 

Our lead therapeutic candidate, ATI-2173, is a first-in-class Active Site Polymerase Inhibitor Nucleotide (ASPIN) that is in clinical development as the backbone of an oral, once-daily potential curative therapy for HBV. To-date, we have completed extensive pre-clinical work, as well as Phase 1 studies in both healthy volunteers and HBV-infected individuals. A Phase 2a study of ATI-2173 is [currently underway expected to initiate in the first quarter of 2021] 
